Related resources
Full-text held externally
- DOI: 10.1038/sj.gt.3302638
- PMID: 16163377
- UKPMCID: 16163377
Search for item elsewhere
University researcher(s)
Academic department(s)
Permanent partial phenotypic correction and tolerance in a mouse model of hemophilia B by stem cell gene delivery of human factor IX.
Bigger, B W; Siapati, E K; Mistry, A; Waddington, S N; Nivsarkar, M S; Jacobs, L; Perrett, R; Holder, M V; Ridler, C; Kemball-Cook, G; Ali, R R; Forbes, S J; Coutelle, C; Wright, N; Alison, M; Thrasher, A J; Bonnet, D; Themis, M
Gene therapy. 2006;13(2):117-26.
Access to files
Full-text and supplementary files are not available from Manchester eScholar. Full-text is available externally using the following links:
Full-text held externally
- DOI: 10.1038/sj.gt.3302638
- PMID: 16163377
- UKPMCID: 16163377
Abstract
Immune responses against an introduced transgenic protein are a potential risk in many gene replacement strategies to treat genetic disease. We have developed a gene delivery approach for hemophilia B based on lentiviral expression of human factor IX in purified hematopoietic stem cells. In both normal C57Bl/6J and hemophilic 129/Sv recipient mice, we observed the production of therapeutic levels of human factor IX, persisting for at least a year with tolerance to human factor IX antigen. Secondary and tertiary recipients also demonstrate long-term production of therapeutic levels of human factor IX and tolerance, even at very low levels of donor chimerism. Furthermore, in hemophilic mice, partial functional correction of treated mice and phenotypic rescue is achieved. These data show the potential of a stem cell approach to gene delivery to tolerize recipients to a secreted foreign transgenic protein and, with appropriate modification, may be of use in developing treatments for other genetic disorders.